Company Overview and News
The top three positions are Twenty-First Century Fox, Seagate Technology, and Alliance Data Systems and they add up to ~45% of the portfolio.
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, May 21.
The review time for the new drug application (“NDA”) for Azedra was extended by 3 months. The prescription user fee drug act (“PDUFA”) is set for July 30.
When investors look back at the history of Valeant Pharmaceuticals’ (VRX) turnaround, they will remember May 8, 2018. Management’s earnings call for the first quarter is an inflection point for the company as the company builds on revenue growth and higher profits. The company has three catalysts that will lead the stock to a minimum $30 share price. That is, a forward P/E multiple of at least 8 times on sales growth of between 15 – 20 percent, annually.
This fund is currently trading at an attractive discount of -8.81% with a 1-year z-score of -1.00.
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking John Paulson's Paulson & Co. Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.
Shares of fallen nearly 70% year to date but appear to be ready to fill the gap back to the psychologically important $1 level.
Soros' 13F portfolio value increased from $4.37B to $6.16B this quarter. The number of positions increased from 196 to 219.
On Tuesday, Mizuho Securities analyst Irina Koffler dished out a rather dramatic upgrade of Valeant Pharmaceuticals (VRX). Raising it from “Neutral” to “Buy” was significant, though not earth-shattering. The head-turner was the improved price target. Koffler had thought VRX stock was worth $15, but upped her target to a whopping $27 per share.
Professor Aswath Damodaran joins Behind the Idea this week to discuss Facebook and his broader investing (and life) philosophy.
Jim Chanos is the man, that I can tell you. Barry’s new interview with the legendary money manager and short-seller has too many highlights for me to list individually.
You can stream/download the full conversation, including the podcast extras on iTunes, Bloomberg, Overcast, and Soundcloud. Our earlier podcasts can all be found on iTunes, Soundcloud, Overcast and Bloomberg.
This week, we speak with famed short seller Jim Chanos, founder and president of Kynikos Associates LP, the world’s largest exclusive short-selling investment firm.
Good afternoon and welcome to the PDL BioPharma's earnings conference call for the first quarter 2018. Today's call is being recorded. For opening remarks and introductions, I would now like to turn the call over to Pete Garcia, Chief Financial Officer of PDL.
Shares of Valeant Pharmaceuticals Inc. (VRX - Free Report) have rallied 11.5% after the company reported better-than-expected results for the first-quarter results on May 8. The increase in guidance for 2018 was encouraging too.
2017-09-28 - Asif
Valeant Pharmaceuticals International, Inc. is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. We are diverse not only in our sources of revenue from our broad drug and medical device portfolio, but also among the therapeutic classes and geographies we serve. We generated revenues of $4,342 million and $4,792 million for the six months ended June 30, 2017 and 2016, respectively. Our portfolio of products falls into three reportable segments: (i) Bausch + Lomb/International, (ii) Branded Rx and (iii) U.S. Diversified Products. The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products a...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...